Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Recommendation of "Hold" by Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have earned a consensus recommendation of "Hold" from the four brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $16.67.

A number of research analysts have recently commented on the company. Mizuho raised Atara Biotherapeutics from a "neutral" rating to an "outperform" rating and lowered their price objective for the company from $25.00 to $18.00 in a report on Friday, August 16th. Canaccord Genuity Group increased their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, HC Wainwright restated a "neutral" rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ATRA. Delap Wealth Advisory LLC acquired a new stake in Atara Biotherapeutics in the 1st quarter worth $29,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics during the second quarter valued at about $53,000. Cubist Systematic Strategies LLC bought a new position in Atara Biotherapeutics during the second quarter valued at about $79,000. State Street Corp raised its holdings in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company's stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock worth $204,000 after acquiring an additional 7,381 shares during the period. Institutional investors own 70.90% of the company's stock.

Atara Biotherapeutics Price Performance

ATRA traded down $0.67 during midday trading on Monday, hitting $11.33. 110,585 shares of the company's stock traded hands, compared to its average volume of 107,325. The company has a market cap of $65.26 million, a PE ratio of -0.44 and a beta of 0.50. The stock's fifty day simple moving average is $9.05 and its 200-day simple moving average is $10.14. Atara Biotherapeutics has a one year low of $6.50 and a one year high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the firm posted ($16.50) EPS. On average, research analysts expect that Atara Biotherapeutics will post -12.12 EPS for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.